Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants

VRC01 is being evaluated in the AMP efficacy trials, the first assessment of a passively administered broadly neutralizing monoclonal antibody (bnAb) for HIV-1 prevention. A key analysis will assess serum VRC01-mediated neutralization as a potential correlate of protection. To prepare for this analy...

Full description

Bibliographic Details
Main Authors: Yunda Huang, Lily Zhang, Amanda Eaton, Nonhlanhla N. Mkhize, Lindsay N. Carpp, Erika Rudnicki, Allan DeCamp, Michal Juraska, April Randhawa, Adrian McDermott, Julie Ledgerwood, Philip Andrew, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mgodi, Myron Cohen, Lawrence Corey, John Mascola, Peter B. Gilbert, Lynn Morris, David C. Montefiori
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
population pharmacokinetic modeling
pharmacokinetics/pharmacodynamics joint modeling
correlates analysis
monoclonal antibodies
hiv-1 prevention
broadly neutralizing antibody
breakthrough viruses
Online Access:http://dx.doi.org/10.1080/21645515.2021.1908030

Internet

http://dx.doi.org/10.1080/21645515.2021.1908030

Similar Items